Company Statements

September 28, 2023

Gilead Sciences Statement on Phase 3 Obeldesivir Clinical Trials in COVID-19: BIRCH Study to Stop Enrollment While OAKTREE Study Nears Full Enrollment

September 26, 2023

Gilead Statement on the Discontinuation of Magrolimab Study in AML with TP53 Mutations

July 22, 2023

Gilead Statement on New York Times’ Story on TDF and TAF Development for HIV

June 30, 2023

Gilead Prevails in HIV Antitrust Trial

May 09, 2023

Gilead Statement on Favorable Verdict in HIV PrEP Patents Litigation

April 03, 2023

Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts

March 30, 2023

Gilead Sciences Statement on Sustaining Access to AmBisome® in Low- and Middle-Income Countries

February 17, 2023

Christi Shaw to Depart Gilead and Kite Leadership End of Q1

February 09, 2023

Gilead Sciences Commends Convictions in Counterfeiting Scheme, Pledges Continued Commitment to Protect Patients